CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
6.29
+0.09 (1.45%)
Sep 2, 2025, 4:00 PM - Market closed
CNS Pharmaceuticals Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for CNS Pharmaceuticals.
Price Target: $ (0.00%)
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for CNS Pharmaceuticals is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 25, 2025 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $300 | Hold → Strong Buy | Upgrades | $300 | +4,669.48% | Sep 10, 2024 |
| Brookline Capital | Brookline Capital | Strong Buy Initiates $9,000,000 | Strong Buy | Initiates | $9,000,000 | +143,084,160.73% | Feb 2, 2021 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Initiates $9,900,000 | Strong Buy | Initiates | $9,900,000 | +157,392,586.80% | Aug 24, 2020 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-276.20
from -466.45
EPS Next Year
-16.89
from -276.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -37.80 | -14.49 | ||
| Avg | -276.20 | -16.89 | ||
| Low | -495.45 | -18.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.